VTYX Q3 2025 Earnings — Ventyx Biosciences, Inc. Revenue & Financial Results | Market Cap Arena

VTYXVentyx Biosciences, Inc.

$1B

Q3 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$25M

Net Income

-$23M

EPS (Diluted)

$-0.32

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$18M

Free Cash Flow

-$18M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$211M

Total Liabilities

$20M

Stockholders' Equity

$191M

Cash & Equivalents

$32M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$25M	-$39M	+35.5%
Net Income	-$23M	-$35M	+35.2%